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Abstract
Background: Statins are cholesterol-lowering drugs that are widely used to reduce the risk of
cardiac infarction. Their beneficial clinical effects, however, are not restricted to their influence on
cholesterol production. As several studies have shown that they have a potency of relaxing blood
vessels.
Methods: We measured the effects of statins on the intracellular free calcium concentration
([Ca2+]i) in human umbilical vein endothelial cells (HUVEC) after acute application and 24-h-
preincubation of statins.
Results: Incubation of the cells for 24 h with cerivastatin or fluvastatin significantly increased the
resting [Ca2+]i. For cerivastatin this effect manifested at a concentration of 1 µM. Increase of resting
[Ca2+]i in the presence of cerivastatin also occurred when the nitric oxide synthase was inhibited.
Transient Ca2+ release induced by histamine was not affected.
Conclusions: The increase of resting [Ca2+]i after incubation with cerivastatin or fluvastatin may
provide an explanation for the direct effects of statins on the endothelial-dependent vasodilatation
and restoration of endothelial activity in vivo.
Background
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase (statins) are drugs widely used in
the treatment of hypercholesterolaemia. A large number
of clinical trials (4S, CARE, WOSCOPS) has demonstrated
that treatment of patients with statins reduces the number
of cardiac or cerebral ischaemic events even in the absence
of further reduction in serum cholesterol levels [15,16].
In addition to their lipid-lowering activity, statins seem to
possess relevant properties that target multiple mecha-
nisms contributing to the progression of arteriosclerosis:
leucocyte adhesion, macrophage stimulation, inflamma-
tory responses, smooth muscle cell activation, and
endothelial dysfunction. In patients with moderate hyper-
cholesterolaemia, treatment with simvastatin improved
both the acetylcholine-stimulated and basal nitric oxide
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mediated vasodilatation measured by use of strain-gauge
plethysmography within one month [14]. Simvastatin
produced relaxation of small resistance arteries of the rat
through a mevalonate sensitive pathway [1]. Moreover, it
was shown that simvastatin and atorvastatin reduced the
concentration of endothelin 1 (ET-1) via a decreased
expression of pre-pro ET-1 mRNA in bovine aortic
endothelial cells. This effect persisted after the addition of
oxidized low-density lipoprotein cholesterol [7]. Various
statins inhibited superoxide anion (O2
-) formation and
improved nitric oxide (NO) dependent vasodilatation
through an influence on the NO/O2
- balance in the vessel
wall [18].
In endothelial cells, after treatment with simvastatin and
lovastatin an up to 3.8 fold increase of eNOS expression
was measured [9]. Other experiments have provided evi-
dence for improved NOS mRNA stability after treatment
with simvastatin [10]. Further it was shown that pravasta-
tin and simvastatin increased the endothelium-dependent
vasorelaxation in aortic rings and also the NO production
by cultured bovine aortic endothelial cells [8].
Although these properties of statins may be relevant for
their beneficial effects on cardiovascular diseases, they do
not elucidate the signal pathway of statins on acute
endothelium-dependent relaxation of blood vessels.
eNOS is a calmodulin-binding enzyme and is abundantly
expressed in endothelial cells. An increase of the cytosolic
free calcium concentration subsequent to receptor stimu-
lation through agonists like histamine or bradykinin is the
main signal for stimulation of synthesis of NO in
endothelial cells.
The aim of the present study was therefore to investigate
the possible role of free intracellular calcium in the path-
way of statin-induced endothelium dependent relaxation.
For this purpose we examined the influence of two differ-
ent statins (cerivastatin and fluvastatin) on agonist-
induced transients and resting levels of [Ca2+]i in cultured
human endothelial cells.
Methods
Endothelial cells from human umbilical vein (HUVEC-p,
Promocell, Heidelberg, Germany) were cultured in EGM-
MV Bulletkit medium (BioWhittaker, Verviers, Belgium)
containing 0.1% human endothelial growth factor, 0.1%
hydrocortison, 5% human serum, 0.4% bovine brain
extract, 0.1% gentamycin. Cultures were maintained at
37°C in a fully humidified atmosphere with 5% CO2 up
to passage 6. SH-SY5Y human neuroblastoma cells
(DSMZ Braunschweig, Germany) were cultured in DMEM
medium containing 10% fetal calf serum (Gibco, Life
Technologies, Eggenstein, Germany) in 10% CO2. Cells
were detached from the culture bottles by exposure to 0.5
g/l trypsin in a Ca2+- and Mg2+-free solution for approxi-
mately 180 s and plated on gelatine-coated glass
coverslips.
Changes of [Ca2+]i were measured fluorimetrically. The
plated cells were loaded with Fura-2-AM (Molecular
Probes, Eugene, USA) by incubating them for 40 min and
37°C at a dye concentration of 1 µM. After incubation,
cells were washed 2 times with Krebs solution (see below)
to remove extracellular Fura-2-AM. Fluorescence measure-
ments were performed with a combination of a scanning
monochromator and a CCD camera operated by TILLvi-
sION software (Till Imago, T.I.L.L Photonics, Gräfelfing,
Germany). The camera was mounted to an inverted
microscope (Axiovert 100, Carl Zeiss, Jena, Germany)
with a 40x objective (Neofluar, Carl Zeiss). Cells were
exposed to alternating excitation light pules of 340 and
380 nm wavelength of each 200 ms at intervals of 2 s.
Emission images were collected during these pulses. Fluo-
rescence values were corrected for background fluores-
cence before starting data collection from the emission
images. Per experiment up to 8 cells were analyzed simul-
taneously by defining corresponding areas of interest in
the images. The fluorescence intensity ratio (FR), which is
related to [Ca2+]i, was calculated for single cells over the
whole experiment by forming the ratio of the fluorescence
values at 340 and 380 nm excitation: FR = F340 / F380 [6].
During the measurements, cells were continuously super-
fused with Krebs solution containing (in mM): NaCl 140,
KCl 6, CaCl2 1.5, MgCl2 1.2, HEPES 11.5, Glucose 10 and
adjusted to pH 7.3 with 1 M NaOH; osmolarity was 295
mOsm. The application of all solutions was performed
with an application tip located 3 mm away from the meas-
ured cells.
Cerivastatin (Bayer AG, Leverkusen, Germany) and fluvas-
tatin (Novartis Pharma AG, Basel, Switzerland) were gen-
erously supplied by the respective companies.
Cerivastatin and fluvastatin were dissolved in water [13].
N-Omega-Nitro-L-Arginine (L-NAME) and histamine
were purchased from Sigma-Aldrich Chemie
(Taufkirchen, Germany).
To examine the long-term effects of statins on intracellular
calcium homeostasis, cells were treated with the statins
one day after seeding by adding appropriate volumes of
stock solutions to the cell culture. Cells kept under the
same conditions, but without statin treatment, served as
control groups.
After 24 h statin incubation the cells were loaded with
Fura-2-AM. FR was measured for 20 s under resting condi-
tions, followed by an application of 10 µM histamine for
60 s and washed out for about 120 s. The mean value ofBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/4
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FR of each cell measured over 10 s was used for further
analysis. To calculate the changes of FR after 24 h incuba-
tion of statins, the FR-values of the incubated cells were
normalized by dividing them through the average FR
value of all control cells of the respective experimental
cycle resulting in FRn.
In order to test the effect of acute application of statins,
cells were incubated with Fura-2-AM as described above
1–2 days after seeding. Cells were superfused with control
solution for 1 min in the experimental setup. Subse-
quently, histamine was applied up to three times at con-
centrations of 1–50 µM followed by a washout with
control solution for 1–2 min. Statins were applied in con-
centrations of 50 and 100 µM to resting cells as well as
during stimulation with 10 µM histamine.
All experiments were performed at room temperature
between 20 and 23°C. Means ± SEM (n = number of cells)
were calculated from pooled FRn. Statistical significance
was tested by means of the two-sided Student's t-test.
Results
The long-term effect of statins on the resting intracellular
calcium concentration was measured by preincubation of
HUVEC cells for 24 h with the respective statins. Since the
resting [Ca2+]i  levels varied from batch to batch, we
expressed the statin effects as FRn, i.e. always normalized
the fluorescence ratio to the values obtained from non-
treated control cells. For 10 µM cerivastatin the FRn value
was 1.104 ± 0.0103 (n = 72, P < 0.01). This means that sta-
tin incubation increased FR, which is a direct measure for
an increase of the intracellular free calcium concentration,
by 10.4%. 5 µM cerivastatin also increased FRn to 1.104 ±
0.0237 (n = 17) and 1 µM cerivastatin to 1.08 ± 0.0113 (n
= 29). For 0.1 µM cerivastatin FRn was 1.01 ± 0.0122 (n =
30) which was not significantly increased (P = 0.29). Incu-
bation with 10 µM fluvastatin increased FRn to 1.117 ±
0.0263 (n = 25, P < 0.01).
Thus, as summarized in Fig. 1, cerivastatin and fluvastatin
significantly increased the fluorescence ratio under resting
conditions.
The dependency of statin induced [Ca2+]i increase on the
driving force for Ca2+ was tested by application of extracel-
lular solution containing 10 mM CaCl2. Application of
the 10 mM CaCl2 solution up to 4 min did not change the
resting calcium concentration of the cerivastatin treated
cells (10 µM, 24 h). Application of nominally Ca2+ free
solution over up to 3 min did not change the resting
[Ca2+]i either.
To investigate whether the increase of [Ca2+]i after statin
incubation is specific to endothelial cells, we repeated the
protocol with SH-SY5Y human neuroblastoma cells. Incu-
bation with 10 µM cerivastatin did not lead to a signifi-
cant change in FRn (0.972 ± 0.0106, n = 23, P = 0.14).
Although endothelial cells do not express G kinase, Volk
et al. have observed an NO-induced transient increase of
[Ca2+]i [17]. To check whether the increase of [Ca2+]i after
incubation with statins was caused by an increase of NO
due to a direct activation of eNOS by statins, we tested the
effect of cerivastatin in the presence of L-NAME, an inhib-
itor of eNOS. L-NAME alone had no effect on FRn. As
shown in Fig. 1, 10 µM Cerivastatin increased FRn also in
the presence of 50 µM L-NAME. Thus, we conclude that
the observed effect of the statins on the resting calcium
concentration is not a phenomenon common to all cells.
In addition, it is not mediated by an direct (Ca2+-inde-
pendent) effect of the statins on NO.
After 24 h incubation with one of the statins (or control
group without statin) cells were stimulated with 10 µM
histamine. Almost all cells have shown a typical increase
of [Ca2+]i (like those shown in Fig. 2). There was no obvi-
ous difference in the stimulated calcium transient pattern
between the statin group and control group. Because of
the large intercellular variability of the quantitative cal-
cium response it was impossible to apply statistics for
comparison between groups.
We further examined the effect of acute statin application
to HUVEC cells on the resting [Ca2+]i level as well as on
histamine-induced Ca2+ release. Cerivastatin or fluvasta-
tin at concentrations between 50 and 100 µM were
directly applied to the cells. In the absence of agonist,
application of the statins for 1 to 5 min did not result in
an effect on resting levels of [Ca2+]i. In Fig. 2A such control
applications are shown for fluvastatin.
The putative influence of statins on agonist-induced tran-
sients of [Ca2+]i was tested with various protocols. As a
control, a first Ca2+ transient was elicited with histamine
only. The subsequent Ca2+ transient, again elicited with
histamine, was then measured during simultaneous (Fig.
2B) or preceded statin application (Fig. 2C). In another
series of experiments, statins were applied after the initial
increase of [Ca2+]i responding to the application of hista-
mine, in order to test whether statins might primarily
affect the return of [Ca2+]i to basal levels. In none of these
experiments histamine-induced Ca2+ signals in HUVEC
cells were significantly altered by statins.
Discussion
There is ample of evidence for so-called pleiotropic effects
of statins – beneficial and vasoprotective effects which are
independent on the lipid-lowering properties of these
substances. Various authors have shown that statins areBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/4
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capable of modulating the flow properties of blood ves-
sels. In vivo studies have shown after a short period of sta-
tin administration to humans a significantly increased
blood flow under resting conditions and after stimulation
[14].
The underlying mechanism for this phenomenon is not
completely understood. The results of Alvarez de
Sotomayor et al. suggest that the improved vasodilatation
is mainly mediated by an endothelium dependent relaxa-
tion which is induced by an increased production of nitric
oxide [1]. An up-regulation of eNOS apparently plays an
important role for this process [3,10]. However, not only
an up-regulation of eNOS expression may be responsible
for a statin-induced increase of blood flow. Also the direct
activation of eNOS is likely to contribute to endothelium
dependent relaxation [19].
Beside the activation of eNOS by mechanic stress, the cal-
cium-calmodulin dependent activation of the enzyme in
association with receptor-dependent and -independent
agonists is the main pathway for the activation of eNOS;
in contrast to iNOS, the activity of eNOS tightly correlates
with [Ca2+]i [4,5].
The concentration of free Ca2+ in the cytosol is extremly
low, whereas the concentration in the extracelluar space
and in the endoplasmatic reticulum is high. When a sign-
aling molecule like Histamin binds to a G-protein-linked
receptor, phospholipase C-β becames activated. This
enzyme generates two products: inositol triphosphate
(IP3) and diacylglycerol. IP3 binds to IP3-gated Ca2+-
release channels in the ER membrane. Ca2+ rushes into the
cytosol, dramatically increasing the local Ca2+ concentra-
tion and triggering Ca2+-responsive proteins in the cells
like eNOS: Ca2+ binds to Calmodulin, a specific Ca2+
Effect of 24-h statin incubation on the resting free calcium concentration Figure 1
Effect of 24-h statin incubation on the resting free calcium concentration. "Control" represents the mean fluorescence ratio 
(FR) of control cells and was set to 1. The other entries are FR values normalized to the mean FR of the respective control 
cells. The type of incubation, the SEM values as well as the number of analyzed cells (n) are indicated. The last line shows 
experiments in which human SH-SY5Y neuroblastoma cells were incubated for 24 h with 10 µM cerivastatin. All other experi-
ments were performed with HUVEC cells.
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binding protein. It undergoes a conformational change
when it binds Ca2+, but it has no encyme activity itself. It
acts by binding to other proteins and therby altering their
activity. In this way it activates eNOS. It is well docu-
mented that IP3-mediated Ca2+ release is also controlled
by cytoplasmatic Ca2+ concentration [11]. Small increases
in calcium concentration around 100–300 nm enhance
the activity of the IP3 receptor dramatically.
With the presented experimental results we have shown a
small but significant increase in resting levels of [Ca2+]i
induced by treatment with cerivastatin and fluvastatin.
This small increase of [Ca2+]i possibly represents a major
contribution to the enhancement of endothelium derived
relaxation of blood vessels in vivo and in vitro, since allos-
teric regulation of eNOS by calcium-calmodulin and the
modulation of IP3 receptor activity by intracellular cal-
cium can multiply this effect.
It is difficult to compare an endothelium cell under rest-
ing conditions with an endothelium cell in an intact
blood vessel under normal flow conditions. However, our
results are in accordance with the investigation of O'Dris-
coll et al. that indicates that L-NAME-mediated vasocon-
striction is enhanced after treatment with statins,
indicative of an augmented basal effect of NO [14].
After 24 h incubation with statins we could not observe
obvious changes of histamine-induced Ca2+ transients.
Because of a broad intercellular variety of histamine-
induced Ca2+  transients, a quantitative comparison
between groups was not feasible. Furthermore, direct
comparison of the Ca2+ response to histamine for one cell
before and after incubation with statins was technically
not possible.
We did not find any acute effect of statin treatment on
[Ca2+]i. This result is in accordance with the described in
vivo results. Because of the broad intercellular variety in
agonist-induced Ca2+ signals in HUVEC cells and the long
lasting statin incubation it will not be feasible to perform
experiments on single cells to explore the role of the intra-
cellular calcium stores and calcium pumps for the
observed effects.
One possible pathway leading to the increase in [Ca2+]i
after incubation with statins could be via an increase of
NO by means of direct eNOS activation by statins [17]. To
exclude this hypothesis we compared cells incubated with
10 µM cerivastatin alone and cells incubated with 10 µM
cerivastatin and 50 µM L-NAME as an inhibitor for the
eNOS. In contrast to other L-Arginine inhibitors like L-
NMMA, L-NAME has a different selectivity to the three
NOS isoforms. The selectivity iNOS / eNOS is reported
with 0,05 and the pIC50 with 5,82 for human isoencymes
[2]. So, L-NAME is not highly active for eNOS inhibition,
but for the applied concentration of 50 µM in HUVEC we
expected a satisfied and selective inhibition of eNOS.
Because there was no significant difference of the changes
of the on [Ca2+]i caused by cerivastation with or without
L-NAME, we conclude that the observed effects of statins
on [Ca2+]i are not indirectly mediated by NO.
Conclusions
Incubation of the cells for 24 h with cerivastatin or fluvas-
tatin significantly increased the resting [Ca2+]i. Increase of
resting [Ca2+]i in the presence of cerivastatin also occurred
when the nitric oxide synthase was inhibited. Transient
Ca2+  release induced by histamine was not affected.
Histamine-induced transients in [Ca2+]i Figure 2
Histamine-induced transients in [Ca2+]i. (A) Fluorescence 
ratio of 3 cells. Application of 50 µM fluvastatin without ago-
nist followed by the application of histamine (50 µM) and flu-
vastatin again. Compared with histamine, fluvastatin causes 
no changes of [Ca2+]i. The very small waves of the baseline 
after the application of fluvastatin were not distinguishable 
from the normal baseline fluctuations which can always be 
observed when small changes of fluid flow or level in the 
experimental chamber are encountered (also see end of this 
record). (B) Records of the fluorescence ratios of 2 cells. 
Application of 50 µM histamine 3 times, during the second 
stimulation co-application of 50 µM fluvastatin. No specific 
effect caused by the application of fluvastatin was observed. 
The Ca2+ transients elicited by repeated histamine stimula-
tions slightly decrease in amplitude. This is a normal phenom-
enon in endothelial cells and is not related to statin 
application.
1.0
0.5
1.0
0.5
600 400 200 0
Time (s)
A
B
Fluva
Hist
Hist
FluvaPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/4
Page 6 of 6
(page number not for citation purposes)
Recently published results of Mizuno et al. have shown
that there is a clearly quantitative relationship between
the concentration of [Ca2+]i and NO production [12]. The
relationship between the integrated [Ca2+]i and NO pro-
duction was described by a straight line. This encourages
us in the assumption that the observed changes of [Ca2+]i
through statins could be one possible mechanism for the
improvement of endothelial function after treatment with
these substances in vessels challenged by arteriosclerosis.
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